Epoxyeicosatrienoic acids: A double-edged sword in cardiovascular diseases and cancer

Journal of Clinical Investigation

Volumn 122, Issue 1, 2012, Pages 19-22

  Wang, Dingzhi ^a   DuBois, Raymond N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AR 9281; CYTOCHROME P450; CYTOCHROME P450 2J2; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE; BLOOD VESSEL; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; KIDNEY DISEASE; METABOLITE; METASTASIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; EICOSANOIDS; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL;

EID: 84855452538     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61453     Document Type: Note

References (22)

1. Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181-193.
2. Fleming I. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med. 2008;18(1):20-25.
3. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8(10):794-805.
4. Xu X, Zhang XA, Wang DW. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev. 2011;63(8):597-609.
5. Yang Q, Zhang RZ, Yim AP, He GW. Effect of 11,12-epoxyeicosatrienoic acid as an additive to St. Thomas' cardioplegia and University of Wisconsin solutions on endothelium-derived hyperpolarizing factor-mediated function in coronary microarteries: influence of temperature and time. Ann Thorac Surg. 2003;76(5):1623-1630. (Pubitemid 37378324)
6. Shen HC. Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin Ther Pat. 2010;20(7):941-956.
7. Panigrahy D, et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest. 2012;122(1):178-191.
8. Jiang JG, et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 2005;65(11):4707-4715.
9. Chen C, et al. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. J Pharmacol Exp Ther. 2010;336(2):344-355.
10. Pozzi A, et al. The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J Biol Chem. 2010;285(17):12840-12850.
11. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, Busse R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci. 2005;118(pt 23):5489-5498. (Pubitemid 43079290)
12. Jiang JG, et al. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 2007;67(14):6665-6674.
13. Chen C, et al. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther. 2009;329(3):908-918.
14. Homma S, et al. Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity. Clin Exp Immunol. 2009;156(2):344-352.
15. Zagorac D, Jakovcevic D, Gebremedhin D, Harder DR. Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. J Cereb Blood Flow Metab. 2008;28(8):1431-1439.
16. Nithipatikom K, et al. Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci. 2010;101(12):2629-2636.
17. Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res. 2009;50(suppl):S52-S56.
18. Yang W, et al. Characterization of 14,15-epoxyeicosatrienoyl- sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. J Pharmacol Exp Ther. 2007;321(3):1023-1031. (Pubitemid 46762683)
19. Liu Y, et al. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A. 2005;102(46):16747-16752. (Pubitemid 41688848)
20. Fang X, et al. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. Am J Physiol Heart Circ Physiol. 2006;290(1):H55-H63.
21. Cheng LM, et al. The epoxyeicosatrienoic acid-stimulated phosphorylation of EGF-R involves the activation of metalloproteinases and the release of HB-EGF in cancer cells. Acta Pharmacol Sin. 2010;31(2):211-218.
22. Liu L, et al. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther. 2011;339(2):451-463.